Q linea AB

QLINEA · Nasdaq Stockholm · Healthcare

17.05SEK −1.7%last day

Price as of 2 October 2026

The price over the past year, with dividends: −36.3%

Performance

1 month

−10.3%

1 year

−36.3%

3 years, per year

−65.2%

5 years, per year

−74.8%

Largest fall, 3 years

−99.8%

Below the peak now

−99.9%

Volatility, 1 year

54.0%

Return with dividends reinvested.

Key figures

P/E

negative earnings

P/B

1.1

Dividend yield

0.0%

Return on equity

−55.6%

Net margin

–

Market value

32 m USD

Quality, value and trend

Where Q linea stands against every Nordic stock today. 100 is best.

Quality82

Profitability and a sound balance sheet over time. Better than 82% of Nordic stocks.

Value15

The price measured against earnings, assets and cash flow. Better than 15% of Nordic stocks.

Trend22

The price development over the past year. Better than 22% of Nordic stocks.

Combined29

Quality, value and trend together. Better than 29% of Nordic stocks.

About Q linea

Q linea AB is a company in healthcare, listed on Nasdaq Stockholm. The share trades in SEK. It has around 70 employees.

Q-linea AB (publ) engages in the manufacturing and sale of instruments and consumables diagnose and treat infectious diseases in the United Kingdom, the United States, France, the Middle East, Belgium, Italy, and Finland. It offers ASTar, an antimicrobial susceptibility testing (AST) technology used in the treatment of bloodstream infections and sepsis; and ASTar BC G- Kit which contains two disposables, including a sample preparation cartridge and an AST disc, used with the Frozen insert. The company also develops Podler, a portable blood culture technology. It serves physicians, hospitals, laboratories, healthcare payers, and the medical profession.

See the full analysis in InvestWiser.

The accounts, dividends, 40 years of charts and the comparison with other stocks are in the app.

See the full analysis